Followers | 1324 |
Posts | 128332 |
Boards Moderated | 1 |
Alias Born | 08/28/2009 |
Wednesday, July 21, 2021 10:08:28 AM
Palisade Bio Enters into Worldwide In-Licensing Agreement with University of California for Technology to Support Target Identification, Drug Discovery, and Clinical Development
CARLSBAD, Calif., July 13, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it entered into an exclusive license with the Regents of the University of California, expanding its proprietary technology for detecting enzymatic protease activity in human clinical samples. Under the terms of this agreement, in combination with a related 2020 license from UC, the Company receives a worldwide exclusive license to patent rights covering certain engineered substrates and their use in measuring degradative enzymes for disease conditions, including cancer. This technology was originally developed in the laboratory of Dr. Michael Heller at University of California San Diego.
"Many chronic endocrine and inflammatory diseases are associated with chronic proteolytic enzyme leak from the GI tract. We have a deep understanding of the protease biology of the GI tract, and with the license we are expanding our proprietary whole-blood assay to identify the specific protease activity contributing to these diseases. As we expand our pipeline of drug products, these assets form a platform for novel target and drug discovery, as well as highly efficient patient selection and measurement of clinical response during drug development," said Tom Hallam, Ph.D., CEO of Palisade Bio.
My opinions and comments are exactly that. They are not a recommendation to either buy or sell any security.
Recent PALI News
- Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules • GlobeNewswire Inc. • 05/02/2024 12:30:00 PM
- Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) • GlobeNewswire Inc. • 05/01/2024 12:30:00 PM
- Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach • GlobeNewswire Inc. • 04/23/2024 12:30:00 PM
- Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool • GlobeNewswire Inc. • 04/16/2024 12:30:00 PM
- Palisade Bio to Participate in the Virtual Investor Lunch Break Event • GlobeNewswire Inc. • 04/11/2024 01:15:00 PM
- Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™ • GlobeNewswire Inc. • 04/10/2024 12:15:00 PM
- Palisade Bio Announces 1-for-15 Reverse Stock Split • GlobeNewswire Inc. • 04/03/2024 09:30:00 PM
- Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:35:16 PM
- Palisade Bio to Present at Digestive Disease Week (DDW) 2024 • GlobeNewswire Inc. • 02/15/2024 01:35:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:54:03 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:10:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:38:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:36 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/13/2024 07:51:09 PM
- Palisade Bio Provides Corporate Update and Reiterates Guidance • GlobeNewswire Inc. • 02/13/2024 01:35:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:03:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 09:38:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 09:37:40 PM
- Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members • GlobeNewswire Inc. • 02/08/2024 07:40:00 PM
- Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders • GlobeNewswire Inc. • 02/08/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:30:10 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM